Optimizing the clinical effect of OX40 agonism may require novel combination regimens, sequential dosing strategies, or evaluation in selected patients with inflamed tumors.36 37 Further studies are needed to elucidate the therapeutic potential of OX40 agonism for the treatment of advanced cancers. The gene discussed is TNFRSF4; the disease is cancer.